Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Septerna logo — Bringing a new era of GPCR medicines to patients with its Na...

Septerna

Bringing a new era of GPCR medicines to patients with its Native Complex Platform™.

Founded 2022 United States South San Francisco, United States 137 employees IPO Total: $552.60M Biotechnology, Pharmaceutical

General Information

Company Name Septerna
Founded Year 2022
Location United States South San Francisco, United States
Employees 137
Industries Biotechnology, Pharmaceutical
Funding Stage IPO
Business Model B2B, D2C, Platform
Revenue Model Licensing, Performance Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Septerna. To contact Septerna, visit septerna.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Septerna compare?

A PDF of Septerna and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Septerna soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Septerna

Septerna, founded in 2022, is a biotechnology and pharmaceutical company headquartered in the United States. With the slogan, "Bringing a new era of GPCR medicines to patients with its Native Complex Platform™," the company is pioneering innovations in the GPCR landscape.

Septerna aims to transform the potential of GPCR medicines into reality through cutting-edge biochemical, structural, and computational drug discovery methods. The company's hallmark, the Native Complex Platform™, facilitates precise modulation of GPCR biology, thereby expanding small molecule discovery in the field.

The startup has recently attracted significant interest, securing a $302.60M IPO investment as of 01 October 2024. Septerna continues its quest toward revolutionizing patient care by actively seeking talented individuals to join its mission-driven team.

Business keywords: GPCR medicines, Native Complex Platform, small-molecule drugs, drug discovery, biochemical advances, structural drug development, computational drug discovery, pharmacology, high-impact medicines, G protein-coupled receptors, medicinal chemistry, innovation in healthcare, patient-centric solutions, bioscience research

Services & Products

Discovery of GPCR-targeted drug candidates
Development of oral small molecule therapies
Optimization of GPCR drug targets

Target Customers

Patients with unmet medical needs Healthcare providers Medical researchers Pharmaceutical investors

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
IPO $302.60M -
01 Oct 2024
Series B $150.00M 15
Casdin Capital RA Capital Management Third Rock Ventures
Casdin Capital, RA Capital Management +13
01 Jul 2023
Spinout $100.00M 7
Casdin Capital Third Rock Ventures Invus
Casdin Capital, Third Rock Ventures +5
01 Jan 2022

Septerna Alternatives & Competitors

View All Alternatives
Septerna vs
Arrakis Therapeutics
Arrakis Therapeutics United States

Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions o...

52 employees
Biopharma, Biotechnology
Compare Septerna vs Arrakis Therapeutics
Septerna vs
Regor Therapeutics Group
Regor Therapeutics Group China

We aspire to be a world class innovative drug discovery company from China.

35 employees
Biotechnology, Pharmaceutical
Compare Septerna vs Regor Therapeutics Group
Septerna vs
Rgenta Therapeutics Inc.
Rgenta Therapeutics Inc. United States

We unlock the therapeutic potentials of highly disease-relevant targets undruggable by small molecul...

Series A
31 employees
Biotechnology, Health Care
View all alternatives

FAQ About Septerna

Bringing a new era of GPCR medicines to patients with its Native Complex Platform™.
Septerna was founded in 2022.
Septerna is headquartered in South San Francisco, United States.
Septerna operates in Biotechnology and Pharmaceutical. Its work centres on GPCR medicines, Native Complex Platform, small-molecule drugs and drug discovery. Its customers include Patients with unmet medical needs, Healthcare providers and Medical researchers.
Septerna has a B2B, D2C and Platform business model. Its revenue comes from Licensing, Performance Based and Product Sales.
Septerna has approximately 137 employees.
Septerna has completed 3 funding rounds, raising a total of $552.60M. The latest funding stage is IPO.
Septerna offers: Discovery of GPCR-targeted drug candidates, Development of oral small molecule therapies, Optimization of GPCR drug targets.
Top alternatives and competitors to Septerna include Arrakis Therapeutics, Regor Therapeutics Group, Rgenta Therapeutics Inc., Zai Lab, PharmEnable Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Septerna and Arrakis Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Septerna, https://bouncewatch.com/company/septerna, updated 29 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes